318 related articles for article (PubMed ID: 14610412)
1. Management of bone loss in men with prostate cancer.
Higano CS
J Urol; 2003 Dec; 170(6 Pt 2):S59-63; discussion S64. PubMed ID: 14610412
[TBL] [Abstract][Full Text] [Related]
2. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
3. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
4. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy.
Bruder JM; Ma JZ; Basler JW; Welch MD
Urology; 2006 Jan; 67(1):152-5. PubMed ID: 16413352
[TBL] [Abstract][Full Text] [Related]
6. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
Kiratli BJ; Srinivas S; Perkash I; Terris MK
Urology; 2001 Jan; 57(1):127-32. PubMed ID: 11164157
[TBL] [Abstract][Full Text] [Related]
7. Osteoporosis due to androgen deprivation therapy in men with prostate cancer.
Daniell HW
Urology; 2001 Aug; 58(2 Suppl 1):101-7. PubMed ID: 11502461
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
9. Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer.
Panju AH; Breunis H; Cheung AM; Leach M; Fleshner N; Warde P; Duff-Canning S; Krahn M; Naglie G; Tannock I; Tomlinson G; Alibhai SM
BJU Int; 2009 Mar; 103(6):753-7. PubMed ID: 19007370
[TBL] [Abstract][Full Text] [Related]
10. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
Campbell SC; Bhoopalam N; Moritz TE; Pandya M; Iyer P; Vanveldhuizen P; Ellis NK; Thottapurathu L; Garewal H; Warren SR; Friedman N; Reda DJ
Urology; 2010 May; 75(5):1138-43. PubMed ID: 20303574
[TBL] [Abstract][Full Text] [Related]
11. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
[TBL] [Abstract][Full Text] [Related]
12. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for bone loss with prostate cancer in Korean men not receiving androgen deprivation therapy.
Kim SO; Kang TW; Kwon D; Park K; Ryu SB
Int Braz J Urol; 2009; 35(2):183-8; discussion 189. PubMed ID: 19409122
[TBL] [Abstract][Full Text] [Related]
14. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
[TBL] [Abstract][Full Text] [Related]
15. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
16. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
17. The relationship between daily calcium intake and bone mineral density in men with prostate cancer.
Planas J; Morote J; Orsola A; Salvador C; Trilla E; Cecchini L; Raventós CX
BJU Int; 2007 Apr; 99(4):812-5; discussion 815-6. PubMed ID: 17378843
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation therapy for prostate cancer results in significant loss of bone density.
Wei JT; Gross M; Jaffe CA; Gravlin K; Lahaie M; Faerber GJ; Cooney KA
Urology; 1999 Oct; 54(4):607-11. PubMed ID: 10510915
[TBL] [Abstract][Full Text] [Related]
19. [Influence of androgen deprivation therapy on bone mineral density in men with prostate cancer].
Deng J; Li W; Yang L; Wang L; Zou D
Zhonghua Nan Ke Xue; 2004 Oct; 10(10):761-3. PubMed ID: 15562791
[TBL] [Abstract][Full Text] [Related]
20. Approach to the prostate cancer patient with bone disease.
Greenspan SL
J Clin Endocrinol Metab; 2008 Jan; 93(1):2-7. PubMed ID: 18178905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]